Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,897 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06667960RecruitingPhase 1/Phase 2
Study of JK06 for advanced solid tumors
This trial tests a new drug called JK06 for people with advanced solid tumors that cannot be removed by surgery or have spread. It aims to see if JK06 is safe and effective.
AntwerpAges 18 years+ - NCT06667076RecruitingPhase 2
Amivantamab combinations for advanced EGFR-mutant lung cancer
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
Daphne, AlabamaAges 18 years+ - NCT06667544RecruitingPhase 1/Phase 2
Study of RNK08954 for advanced cancers with KRAS G12D mutation
This trial tests a new oral drug called RNK08954 for people with advanced solid tumors that have a specific KRAS G12D genetic change. The drug targets this mutation to try to stop tumor growth. It is for patients who have already had other treatments and may not have many options left.
Nanning, GuangxiAges 18 years+ - NCT05744687RecruitingPhase 2/Phase 3
Letrozole plus SPH4336 versus letrozole alone for breast cancer
This study tests whether adding SPH4336 to letrozole works better than letrozole plus a placebo for treating hormone-receptor–positive, HER2-negative breast cancer in people starting first-line treatment. It may help slow cancer growth more effectively if the added drug is beneficial.
Fuzhou, FujianAges 18–75 - NCT05761223RecruitingPhase 1/Phase 2
Study of FB849 for adults with measurable cancer lesions
This early-stage trial tests whether FB849 is safe and tolerable, how the body handles it, and whether it shows any early signs of helping cancer. You may be able to join if you’re an adult with at least one measurable tumor spot and your health tests meet study requirements.
Cleveland, OhioAges 18 years+ - NCT06663072RecruitingPhase 1
Testing fulvestrant plus lutetium therapy for advanced pancreatic neuroendocrine tumors
This trial tests a new combination of two drugs: lutetium-177 DOTATATE (a type of radiation therapy that targets tumor cells) and fulvestrant (a hormonal therapy). It is for people with advanced pancreatic neuroendocrine tumors that have grown despite previous treatments.
Chicago, IllinoisAges 18 years+ - NCT06662006RecruitingPhase 2
Nal-IRI chemo with immunotherapy and radiation for pancreatic cancer
This trial tests a combination of chemotherapy (Nal-IRI, 5-FU, leucovorin), an immunotherapy drug (PD-L1 inhibitor), and a targeted anti-angiogenic pill, with or without radiation (SBRT), as a second-line treatment for people with metastatic pancreatic cancer that has progressed after first-line therapy.
Nanjing, JiangsuAges 18–75 - NCT06659952Recruiting
HIV+ donor hearts for HIV+ recipients
This trial tests whether hearts from donors who had HIV can be safely transplanted into people with HIV who need a heart transplant. It may offer a new option for those on the waiting list.
Dallas, TexasAges 18 years+ - NCT06657157Recruiting
Nerve side effects study for new bladder cancer treatment
This study watches for nerve problems in people getting enfortumab vedotin and pembrolizumab as their first treatment for advanced bladder cancer. It aims to understand how common these side effects are and how they affect patients.
Augsburg, BavariaAges 18 years+ - NCT06084299RecruitingPhase 1
Immune cell therapy for advanced liver cancer
This trial tests a new treatment using your own immune cells (tumor-infiltrating lymphocytes) to fight advanced liver cancer. It is for people whose cancer has progressed after at least two standard treatments and who have tumors that can be biopsied to grow these cells.
WuhanAges 18–70 - NCT06655480RecruitingPhase 2
Triple drug therapy for advanced heart failure with preserved ejection fraction
This trial tests a combination of three heart failure drugs (ARNI, SGLT2i, MRA) to see if they improve symptoms and outcomes in people with a type of heart failure where the heart pumps normally but doesn't relax properly (HFpEF).
MoscowAges 40–80 - NCT06655246RecruitingPhase 1
Ziftomenib and imatinib for advanced GIST
This trial tests a new drug, ziftomenib, combined with imatinib for people with advanced or spreading gastrointestinal stromal tumors (GIST) that have a KIT mutation. It may help if your GIST has gotten worse while on imatinib.
Birmingham, AlabamaAges 18 years+ - NCT06647680RecruitingPhase 2
Chemo and immunotherapy before surgery for rectal cancer
This trial tests a combination of chemotherapy and an immunotherapy drug (a PD-1 inhibitor) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
Qingdao, ShandongAges 18–75 - NCT06650163RecruitingPhase 1
New imaging test for brain tumor surgery planning
This trial tests a new kind of PET scan that uses a special tracer (Zr-89 crefmirlimab berdoxam) to help doctors see brain tumors more clearly before surgery. If you are scheduled to have your brain tumor removed, this scan may give your surgeon extra information to guide the operation.
Los Angeles, CaliforniaAges 18 years+ - NCT06647836Enrolling by invitation
Immunotherapy for advanced lung squamous cancer
This trial tests how well immunotherapy works as a first treatment for advanced lung squamous cell carcinoma, either alone or with chemotherapy. It aims to see if this approach can help patients who haven't had prior cancer treatment.
Wuhan, HubeiAges 18–80 - NCT06648096RecruitingPhase 1/Phase 2
Testing afatinib for head and neck cancer in Fanconi anemia patients
This trial tests whether the targeted drug afatinib can shrink advanced head and neck cancers in people who also have Fanconi anemia. It is for patients whose tumors cannot be surgically removed and have not responded to or cannot have other standard treatments.
HanoverAges 18 years+ - NCT06651554Recruiting
Suicide prevention app study for teens in Bogota
This trial tests a digital platform designed to help prevent suicide among teenagers. It aims to make mental health support more accessible for students in Bogota schools.
Bogotá, ColombiaAges 14–19 - NCT06649331RecruitingPhase 2
Re-trying antibody-drug conjugates for advanced breast cancer
This study looks at whether giving a different antibody-drug conjugate (ADC) after a previous one can help people with advanced or metastatic breast cancer. It aims to find new options for patients who have already had ADC treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06652048RecruitingPhase 2
High-dose Furmonertinib for advanced lung cancer after progression
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06648057Recruiting
Predictors of response in biliary tract cancer
This trial is looking at how certain markers in your blood or tissue (biomarkers) might predict how well the combination of Lenvatinib and Pembrolizumab works against advanced biliary tract cancer. If you're already scheduled to receive these two drugs, researchers want to learn more from your samples to help future patients.
Seongnam-si, Gyeonggi-doAges 20 years+ - NCT06655376RecruitingPhase 4
Aspirin study for advanced heart failure with a heart pump
This trial tests if taking aspirin along with a standard blood thinner helps people with a HeartMate3 heart pump have fewer bleeding or clotting problems. It is for people who have had their pump for at least 3 months.
Chicago, IllinoisAges 18 years+ - NCT05446467RecruitingPhase 2
Pembrolizumab before surgery for advanced head and neck cancer
This trial studies whether pembrolizumab, given before surgery, can improve outcomes for certain people with stage III–IVA head and neck squamous cell cancer. It’s typically added alongside low-dose PFAS as part of treatment leading up to standard surgery and afterward medicines/radiation.
Qingdao, ShandongAges 18–85 - NCT06644755RecruitingPhase 1
First-in-human study of DS-2243a for advanced cancers
This trial tests a new drug called DS-2243a for people with advanced solid tumors that have stopped responding to standard treatments. It targets a specific protein found in some cancers, and you need to have a particular immune system marker for it to work.
Boston, MassachusettsAges 18 years+ - NCT06644300RecruitingPhase 1
Study of BM230 for advanced solid tumors with HER2
This trial tests a new drug called BM230 for people with advanced solid tumors that have HER2 protein or gene changes. It aims to see if the drug is safe and effective for those who have run out of standard treatment options.
Brisbane, QueenslandAges 18 years+
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,897 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.